×

Early movers: WBA, K, CVEO, AAPL, GRUB, OPK & more

A trader on the floor of the New York Stock Exchange reacts to an announcement from the Federal Reserve during the afternoon of March 19, 2014.
Getty Images
A trader on the floor of the New York Stock Exchange reacts to an announcement from the Federal Reserve during the afternoon of March 19, 2014.

Check out which companies are making headlines before the bell:

Walgreen Boots Alliance—Drug store chain operator Walgreen Co. completed its merger with Alliance Boots, with the combined company trading under the "WBA" ticker and the name Walgreen Boots Alliance. Greg Wasson, who had served as Walgreen CEO, is retiring, with Stefano Pessina becoming acting CEO.

KelloggEmerging markets private equity firm Abraaj Group has pulled out of the bidding for Egyptian cereal maker Bisco Misr, leaving only Kellogg in the running.

Opko Health—The pharmaceutical and diagnostics company's shares are rising after stock purchases by chairman Philip Frost over the last week.

CiveoThe provider of housing for oil service workers is rebounding somewhat this morning, after getting slammed Tuesday on a profit warning and a cut in spending because of lower oil prices.

Abercrombie & FitchA judge recommended that a revised settlement of a lawsuit involving the pay of former CEO Michael Jeffries be approved. Another judge had rejected the original settlement three months ago.

AppleThe tech giant is on track to post its first yearly decline in iPad sales since the device was introduced, according to a report from market research firm ABI Research. But the report also said Apple should reverse that trend in 2015, with overall tablet sales rising 16 percent.

Utility stocksThese stocks will be on watch today, with that sector being the year's best performer—but yesterday's worst. 2014's best performing utility stocks include Integrys Energy, Edison International, Entergy Corp, and Pepco Holdings.

GrubHubThe online food delivery service was upgraded to "outperform" from "market perform" at Barrington Research, with a price target of $43 per share.

NeuroDermThe drug maker's stock shares is under pressure this morning after doubling in Tuesday trading. NeuroDerm shares had rallied on an upbeat study involving its drug to treat Parkinson's Disease.


Questions? Comments? Email us at marketinsider@cnbc.com